US Patent

US10463607 — Antipsychotic Injectable Depot Composition

Formulation · Assigned to Laboratorios Farmaceuticos Rovi SA · Expires 2031-05-31 · 5y remaining

Vulnerability score 44/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a composition for delivering an antipsychotic drug, such as risperidone, as an injectable in-situ forming biodegradable implant for extended release.

USPTO Abstract

The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.

Drugs covered by this patent

Patent Metadata

Patent number
US10463607
Jurisdiction
US
Classification
Formulation
Expires
2031-05-31
Drug substance claim
No
Drug product claim
Yes
Assignee
Laboratorios Farmaceuticos Rovi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.